Technology

Introduction to the Biclonics® format

The product candidates in the Merus pipeline are based on the Biclonics® format. Biclonics® are bispecific, full length human IgG antibodies. Merus exploits a suite of technologies integrating the generation of large panels of high quality human antibodies and their rapid conversion into thousands of Biclonics® ready for functional screening in clinically relevant assays.

Human antibody generation
Merus uses its proprietary transgenic mouse MeMo® for the generation of diverse and high-quality panels of common light chain human monoclonal antibodies.
Biclonics® format
The product programs in the Merus pipeline are based on the Biclonics® format. Biclonics® are bispecific, full length human IgG antibodies.
Predictable in vivo behaviour
Data suggests that Biclonics® have IgG-like half life properties and low immunogenicity in humans.
Biclonics® high-throughput functional screening
Our functional screening assay has allowed us to learn that specific target combinations are indeed new targets and unlock novel biology.
Fc region engineering
CH3 engineered process has yielded essentially pure Biclonics® from single cells. The functional flexibility format of Biclonics® also allows for Fc silencing for added safety and enhanced ADCC (antibody-dependent cell-mediated cytotoxicity) for high potency.
Biclonics® manufacturability
Our Biclonics® manufacturing process has shown stability of >60 passages, yield >1 - >4.0g/L, and is almost identical to the manufacturing process of monoclonal antibodies.
Biclonics® dual target binding
Biclonics® bispecific antibody

Product candidates

Human Biclonics®

Biclonics® are designed to retain the format of antibodies that are produced naturally by the immune system, retaining their favorable attributes including stability and predictability during manufacturing and long half-life and low immunogenicity during treatment of patients.

The new face of fighting cancer

Publications

Scientific publications

For an overview of all publications, please visit the publications overview page.

All publications
October 21, 2018
MCLA-128 ESMO Poster (October 2018)
Poster presented at the European Society for Medical Oncology 2018 Congress, October 19-23, 2018, Munich, Germany
November 4, 2015
Stem Cells AACR-EORTC Poster (April 2015)
May 5, 2018
MCLA-128 PK-PD Analysis Paper
November 11, 2013
Mass Spectrometry Analysis of Antibody Mixtures Paper
August 10, 2012
Mass Spectrometry Analysis of Antibody Mixtures Paper
June 21, 2010
Oligoclonics® Expression Paper
April 3, 2009
Common Light Chain Antibodies Paper
May 14, 2018
MCLA-128 Mechanism of Action Paper
Paper published in Cancer Cell describing MCLA-128 antibody's mechanism of action
June 27, 2017
CH3 Engineering Technology Paper
Paper published in JBC describing Merus proprietary CH3 engineering technology
September 26, 2016
Immuno-Modulatory Receptor poster (September 2016)
Poster presentation, presented at CRI, CIMT, EATI and AACR meeting, September, 2016.
November 9, 2016
MCLA-117 SITC Poster (November 2016)
Poster presentation, presented at the Society for Immunotherapy of Cancer (SITC), Annual Meeting, November, 2016; National HArbour, Maryland, USA.
April 1, 2017
MCLA-158 AACR Poster (April 2017)
Poster presentation, presented at the American Association for Cancer Research, Annual Meeting, April 1-5, 2017; Washington D.C., USA.
April 1, 2017
MCLA-128 AACR Poster (April 2017)
Poster presentation, presented at the American Association for Cancer Research, Annual Meeting, April 1-5, 2017; Washington D.C., USA.
June 2, 2017
MCLA-128 ASCO Poster (June 2017)
Poster presentation, presented at the American Society of Clinical Oncology, Annual Meeting, June 2-6, 2017; Chilago, Illinois, USA.
June 15, 2017
Biopharma Dealmakers – Merus Profile
Published article "Battling Cancer with Bispecific Antibodies" in BioPharma Dealmakers, June 2017.
Aiding the battle against cancer
Martine Boks
Scientist
Robotics are the future of cancer research
Willem Bartelink
Senior Technician

Our team

People behind the science

Are you interested in joining our battle against cancer? To learn more, check out the careers section on our website!

Join our team